W-B Wang1, H Zhang2, M Petzold3, Q Zhao1, B Xu1, G-M Zhao1. 1. <label>*</label>Department of Epidemiology, and Key Laboratory of Public Health Safety, Ministry of Education, Fudan University, Shanghai. 2. <label><sup>†</sup></label>Chinese Center for Disease Control and Prevention, Beijing, China; 3. <label><sup>‡</sup></label>Centre for Applied Biostatistics, Occupational and Environmental Medicine, University of Gothenburg, Sweden.
Abstract
BACKGROUND: Between 2002 and 2008, China's National Tuberculosis Control Programme created the Health X Project, financed in part by a World Bank loan, with additional funding from the UK Department for International Development. OBJECTIVES: To assess the cost-effectiveness of the Project and its impact from a financial point of view on tuberculosis (TB) control in China. METHODS: A decision-analytic model was used to evaluate the cost-effectiveness of the Project. Sensitivity analysis was used to assess the impact of different scenarios and assumptions on results. The primary outcome of the study was cost per disability-adjusted life-year (DALY) saved and incremental DALYs saved. RESULTS: In comparison with alternative scenario 1, the Project detected 1.6 million additional cases, 44 000 deaths were prevented and a total of 18.4 million DALYs saved. The Project strategies cost approximately Chinese yuan (CNY) 953 per DALY saved (vs. CNY1140 in the control areas), and saved an estimated CNY17.5 billion in comparison with the unchanged alternative scenario (scenario 1) or CNY10.8 billion with the control scenario (scenario 2). CONCLUSION: The Project strategies were affordable and of comparable cost-effectiveness to those of other developing countries. The results also provide strong support for the existing policy of scaling up DOTS in China.
BACKGROUND: Between 2002 and 2008, China's National Tuberculosis Control Programme created the Health X Project, financed in part by a World Bank loan, with additional funding from the UK Department for International Development. OBJECTIVES: To assess the cost-effectiveness of the Project and its impact from a financial point of view on tuberculosis (TB) control in China. METHODS: A decision-analytic model was used to evaluate the cost-effectiveness of the Project. Sensitivity analysis was used to assess the impact of different scenarios and assumptions on results. The primary outcome of the study was cost per disability-adjusted life-year (DALY) saved and incremental DALYs saved. RESULTS: In comparison with alternative scenario 1, the Project detected 1.6 million additional cases, 44 000 deaths were prevented and a total of 18.4 million DALYs saved. The Project strategies cost approximately Chinese yuan (CNY) 953 per DALY saved (vs. CNY1140 in the control areas), and saved an estimated CNY17.5 billion in comparison with the unchanged alternative scenario (scenario 1) or CNY10.8 billion with the control scenario (scenario 2). CONCLUSION: The Project strategies were affordable and of comparable cost-effectiveness to those of other developing countries. The results also provide strong support for the existing policy of scaling up DOTS in China.
Authors: Nicolas A Menzies; Gabriela B Gomez; Fiammetta Bozzani; Susmita Chatterjee; Nicola Foster; Ines Garcia Baena; Yoko V Laurence; Sun Qiang; Andrew Siroka; Sedona Sweeney; Stéphane Verguet; Nimalan Arinaminpathy; Andrew S Azman; Eran Bendavid; Stewart T Chang; Ted Cohen; Justin T Denholm; David W Dowdy; Philip A Eckhoff; Jeremy D Goldhaber-Fiebert; Andreas Handel; Grace H Huynh; Marek Lalli; Hsien-Ho Lin; Sandip Mandal; Emma S McBryde; Surabhi Pandey; Joshua A Salomon; Sze-Chuan Suen; Tom Sumner; James M Trauer; Bradley G Wagner; Christopher C Whalen; Chieh-Yin Wu; Delia Boccia; Vineet K Chadha; Salome Charalambous; Daniel P Chin; Gavin Churchyard; Colleen Daniels; Puneet Dewan; Lucica Ditiu; Jeffrey W Eaton; Alison D Grant; Piotr Hippner; Mehran Hosseini; David Mametja; Carel Pretorius; Yogan Pillay; Kiran Rade; Suvanand Sahu; Lixia Wang; Rein M G J Houben; Michael E Kimerling; Richard G White; Anna Vassall Journal: Lancet Glob Health Date: 2016-10-06 Impact factor: 26.763